Kymera Therapeutics' Q2 2025 earnings call highlights clinical progress, Gilead and Sanofi partnerships, and financial strength, setting a strong stage ...

August 16, 2025 10:25 am - Industry revenue for Necitumumab is estimated to rise to $1249.4 million by 2035 from $612.2 million of 2024. The revenue ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Source: Analyst estimates for the quarter provided by FactSet.

Currently exempt from US tariffs, pharmaceutical manufacturers fear steep surcharges, as promised by the US president on ...

Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...